These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

81 related articles for article (PubMed ID: 8111726)

  • 1. A Phase II study of continuous infusion 5-fluorouracil in advanced hormone refractory prostate cancer: an Illinois cancer center study.
    Lokich J
    Cancer; 1994 Mar; 73(5):1536-7. PubMed ID: 8111726
    [No Abstract]   [Full Text] [Related]  

  • 2. A phase II study of continuous infusion 5-fluorouracil in advanced hormone refractory prostate cancer. An Illinois Cancer Center Study.
    Kuzel TM; Tallman MS; Shevrin D; Braud E; Kilton L; Johnson P; Kozlowski J; Vogelzang NJ; Blough R; Benson AB
    Cancer; 1993 Sep; 72(6):1965-8. PubMed ID: 8364875
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Phase II study of repeated single 24-hour infusion of low-dose 5-fluorouracil for palliation in symptomatic hormone-refractory prostate cancer.
    Bex A; Otto T; Lümmen G; Rübben H
    Urol Int; 2002; 69(4):273-7. PubMed ID: 12444282
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Weekly paclitaxel and high-dose 5-fluorouracil plus leucovorin in hormone-refractory prostate cancer: in vitro combined effects and a phase II trial.
    Lin CC; Hsu CH; Hour TC; Cheng AL; Huang CY; Huang KH; Chen J; Pu YS
    Urol Oncol; 2007; 25(3):207-13. PubMed ID: 17483017
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Arterial infusion of 5-FU as a therapeutic adjunct in the treatment of advanced carcinoma of bladder and prostate.
    Nevin JE; Melnick I; Baggerly JT; Landes R; Easley CA
    Va Med Mon (1918); 1975 Aug; 102(8):614-20. PubMed ID: 1163099
    [No Abstract]   [Full Text] [Related]  

  • 6. Continuous infusion of vinblastine for advanced hormone-refractory prostate cancer.
    Dexeus F; Logothetis CJ; Samuels ML; Hossan E; von Eschenbach AC
    Cancer Treat Rep; 1985; 69(7-8):885-6. PubMed ID: 4016795
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Treatment of stage D2 hormone refractory carcinoma of the prostate with 5-fluorouracil and Roferon-A: a Southwest Oncology Group study.
    Marshall ME; Wolf M; O'Rourke M; Barnett TC; Crawford ED
    Cancer Biother Radiopharm; 1996 Apr; 11(2):119-23. PubMed ID: 10851528
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparative trial of adriamycin and 5-fluorouracil in advanced prostatic cancer--progress report.
    DeWys WD; Bauer M; Colsky J; Cooper RA; Creech R; Carbone PP
    Cancer Treat Rep; 1977; 61(2):325-8. PubMed ID: 326401
    [No Abstract]   [Full Text] [Related]  

  • 9. Allopurinol modulation of high-dose fluorouracil toxicity.
    Fox RM; Woods RL; Tattersall MH; Brodie GM
    Lancet; 1979 Mar; 1(8117):677. PubMed ID: 85922
    [No Abstract]   [Full Text] [Related]  

  • 10. Phase I trial of concurrent intraperitoneal and continuous intravenous infusion of fluorouracil in patients with refractory cancer.
    Reichman B; Markman M; Hakes T; Kemeny N; Kelsen D; Hoskins W; Rubin S; Lewis JL
    J Clin Oncol; 1988 Jan; 6(1):158-62. PubMed ID: 3335888
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The continuous arterial infusion of 5-fluorouracil as a therapeutic adjunct in the treatment of advanced carcinoma of the bladder and prostate. A preliminary report.
    Nevin JE; Melnick I; Baggerly JT; Hoffman A; Landes RR; Easley C
    Cancer; 1973 Jan; 31(1):138-44. PubMed ID: 4630227
    [No Abstract]   [Full Text] [Related]  

  • 12. Brachytherapy and continuous infusion 5-fluorouracil for treatment of locally advanced, lymph node negative, prostate cancer: a phase I trial.
    See WA; Dreicer R; Wheeler JA; Forest PK; Loening S
    Cancer; 1996 Mar; 77(5):924-7. PubMed ID: 8608485
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Bisantrene in advanced, hormone-resistant carcinoma of the prostate: an Illinois Cancer Council phase II study.
    Vogelzang NJ; Lanzotti VJ; Muntean B; Blough RR
    Invest New Drugs; 1990 Aug; 8(3):313-5. PubMed ID: 2272771
    [No Abstract]   [Full Text] [Related]  

  • 14. [Continuous venous infusion of 5-fluorouracil (5-FU) under total parenteral nutrition (TPN) in advanced gastric cancer].
    Tane S; Ogawa Y; Kido Y; Ogawa M; Shiozaki H; Miyamoto T; Kokunai I; Watase M; Mori T
    Gan To Kagaku Ryoho; 1985 Dec; 12(12):2322-6. PubMed ID: 3935052
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Arterial infusion of 5-fluorouracil as a treatment for carcinoma of the prostate.
    Nevin JE; Melnick I; Baggerly JT; Estevez J; Landes R; Easley CA
    J Urol; 1974 Jul; 112(1):114-9. PubMed ID: 4209760
    [No Abstract]   [Full Text] [Related]  

  • 16. Continuous 5-fluorouracil infusion causing acute gastric mucosal lesions.
    Suda K; Seki T; Kano Y; Sasagawa M
    Endoscopy; 1993 Aug; 25(6):426-7. PubMed ID: 8404711
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Phase II trial of echinomycin in advanced hormone-resistant prostate cancer. An Illinois Cancer Council study.
    Shevrin DH; Lad TE; Guinan P; Kilton LJ; Greenburg A; Johnson P; Blough RR; Hoyer H
    Invest New Drugs; 1994; 12(1):65-6. PubMed ID: 7960609
    [No Abstract]   [Full Text] [Related]  

  • 18. [Outpatient chemotherapy with continuous intravenous infusion for patients with recurrent renal cell carcinoma or advanced prostate carcinoma].
    Otsuka A; Ono S; Hata M; Ota N
    Gan To Kagaku Ryoho; 1997 Dec; 24 Suppl 4():485-9. PubMed ID: 9429553
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Vinorelbine-based chemotherapy in hormone-refractory prostate cancer.
    Zampino MG; Verri E; Locatelli M; Curigliano G; Ascione G; Sbanotto A; Rocca A; Verweij F; Matei V; Scardino E; Decobelli O; Goldhirsch A; Nolè F
    Anticancer Res; 2006; 26(3B):2375-80. PubMed ID: 16821619
    [TBL] [Abstract][Full Text] [Related]  

  • 20. 5-Fluorouracil versus folinic acid and 5-fluorouracil in advanced, hormone-resistant prostate cancer: a prospective randomized pilot trial.
    Breul J; Jakse G; Forster G; Lampel A; Rohani A; Hartung R
    Eur Urol; 1997; 32(3):280-3. PubMed ID: 9358213
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.